This IP-NFT represents the decentralized pediatric research program focused on Autism Spectrum Disorder (ASD). The underlying study, conducted by O'Ryan Health Rare Disease Series LLC (CRASD Cell) and sponsored by Molecule Science Foundation, is a prospective, observational paired cohort study that uses bulk RNA sequencing of capillary blood samples collected at home via the RedDrop ONE device to validate the BlueSavant AI RNA-based diagnostic model. IRB approval is pending and is included within the approved token budget. The study seeks to identify immune-inflammatory, necroptosis-related, and ASD-associated gene expression signatures with the goal of developing a non-invasive, scalable blood-based diagnostic tool for ASD in children.
Tim Coleman
Research Lead